Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
December 27, 2021
-
REGULATORY Ronapreve Given to Nearly 37,000 People in Japan by November, Xevudy to 270: MHLW
December 24, 2021
-
REGULATORY Japan Seeks Additional Study for Aducanumab, Next Review Might Be Few Years Off
December 23, 2021
-
REGULATORY Gist of FY2022 Drug Pricing Reform
December 22, 2021
-
REGULATORY Japan Likely to Expand PMP Coverage for Add’l Indications, Set 4-Year Grace Period for Spillover Exclusion: 2022 Reform
December 21, 2021
-
COMMENTARY Japan Unlikely to Introduce Medical Fee Incentives for Hospital Formularies in FY2022 Reform
December 20, 2021
-
BUSINESS Astellas to Abolish Pay Structure for Sales Reps, Switching to Company-Wide System Next April
December 20, 2021
-
BUSINESS Pfizer Agrees to Supply Oral COVID-19 Drugs for 2 Million People in Japan
December 20, 2021
-
BUSINESS Biogen to Challenge European Rejection of Aducanumab
December 20, 2021
-
BUSINESS Moderna to Develop All Global Pipeline Assets in Japan without Delay: Local Chief
December 17, 2021
-
BUSINESS Shionogi Pharma Eyes 10 Billion Yen Sales in CDMO Business in FY2022
December 17, 2021
-
REGULATORY Japan Approves Moderna Vaccine for COVID-19 Booster
December 16, 2021
-
REGULATORY Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
-
REGULATORY Aducanumab Up for Japan Advisory Panel Review on December 22
December 15, 2021
-
REGULATORY MHLW Calls for Lifting of Shipment Restrictions for 130 Generic API/Specifications after Survey Finds YOY Rise in Supplies
December 14, 2021
-
BUSINESS Chugai Files Actemra for COVID-19 Pneumonia in Japan
December 14, 2021
-
REGULATORY METI to Dole Out Support for “Dual-Use” Production Bases to Boost Pandemic Preparedness
December 13, 2021
-
REGULATORY Fiscal Discipline for Drug Spending Could Be Discussed towards FY2023: MOF Budget Examiner
December 10, 2021
-
REGULATORY E Keppra Generics from 12 Firms to Join NHI Price List, Patanol and Velcade AGs Too
December 9, 2021
-
ACADEMIA With First Ophthalmologic Biosimilar Set to Debut, Specialist Says Close Attention Required for Unexpected Side Effects
December 9, 2021
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…